281. Clinical Role of the Noninvasive Abdominal Fetal ECG in the Detection and Monitoring of Fetal Tachycardia.
作者: Sian Chivers.;Nicolò Pini.;Shayan Chowdhury.;Ludovica Cicci.;Trisha Vigneswaran.;Vita Zidere.;Sophie Maxwell.;Grace Moriarty.;William Regan.;Eric Rosenthal.;David F A Lloyd.;Thomas G Day.;Owen I Miller.;Gurleen K Sharland.;Barrie Hayes-Gill.;Stephen Niederer.;William P Fifer.;Catherine Williamson.;John M Simpson.
来源: Circ Arrhythm Electrophysiol. 2025年18卷9期e013556页
Fetal tachycardias can cause adverse fetal outcomes including ventricular dysfunction, hydrops, and fetal demise. Postnatally, ECG is the gold standard, but, in fetal practice, echocardiography is used most frequently to diagnose and monitor fetal arrhythmias. Noninvasive extraction of the fetal ECG (fECG) may provide additional information about the electrophysiological mechanism and monitoring of intermittent arrhythmias. Signal processing advances could provide improved data quality impacting clinical translation. The aim of this study was to assess the fetus with known or suspected tachycardia using noninvasive abdominal fECG and correlate results with fetal echocardiography and postnatal ECG.
282. Age-Dependent Contributions of Rare and Common Genetic Variation in Atrial Fibrillation.
作者: Zhanlin Chen.;Peter F Aziz.;Philip Greenland.;Rod Passman.;Adam S Gordon.;Gregory Webster.
来源: Circ Genom Precis Med. 2025年18卷5期e004958页
Genetic variation contributes to atrial fibrillation (AF), but its impact may vary with age. The All of Us Research Program contains whole-genome sequencing of data from 100 574 adult participants with linked electronic health records.
283. Relationships of Circulating Plasma Metabolites With the QT Interval in a Large Population Cohort.
作者: William J Young.;Mihir M Sanghvi.;Julia Ramírez.;Michele Orini.;Stefan van Duijvenboden.;Helen R Warren.;Andrew Tinker.;Pier D Lambiase.;Patricia B Munroe.
来源: Circ Genom Precis Med. 2025年18卷5期e004978页
There is a higher prevalence of heart rate corrected QT (QTc) prolongation in patients with diabetes and metabolic syndrome. QT interval genome-wide association studies have identified candidate genes for cardiac energy metabolism, and experimental studies suggest that polyunsaturated fatty acids have direct effects on ion channel function. Despite this, there has been limited study of metabolite concentration relationships with QT intervals.
284. Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
作者: Brian G DeRubertis.;Ramon L Varcoe.;Prakash Krishnan.;Marc P Bonaca.;David J O'Connor.;Richard Pin.;David C Metzger.;Andrew Holden.;Jen-Kuang Lee.;Osamu Iida.;Ehrin J Armstrong.;Steven W C Kum.;Raghu Kolluri.;Danielle R Bajakian.;Lawrence A Garcia.;Mehdi H Shishehbor.;Shawn Yu.;Karine Ruster.;Brad J Martinsen.;Zsuzsanna Igyarto.;Sahil A Parikh.
来源: Circulation. 2025年152卷15期1076-1086页
Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK randomized controlled trial (Pivotal Investigation of Safety and Efficacy of BRS Treatment-Below the Knee), the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions. This report presents the 2-year safety and efficacy outcomes of the Esprit BTK DRS system in the LIFE-BTK randomized trial comparing DRS with PTA for treatment of infrapopliteal vessels and CLTI.
286. TMVR for the Treatment of Mitral Regurgitation: A State-of-the-Art Review.
作者: Francesco Tartaglia.;Giulia Antonelli.;Mauro Gitto.;Kamil Stankowski.;Dario Donia.;Giulio Stefanini.;Azeem Latib.;Antonio Colombo.;Antonio Mangieri.;Mauro Chiarito.
来源: Circ Cardiovasc Interv. 2025年18卷10期e015298页
Mitral regurgitation is the most common valve disease worldwide. Despite its wide success in inoperable or high-risk surgical patients, transcatheter edge-to-edge repair remains limited by some anatomic features and the non-negligible rate of significant residual regurgitation. Transcatheter mitral valve replacement has emerged as a viable alternative that promises to overcome these issues, but its development has been progressing slowly. This review aims to provide a comprehensive overview of the current state of transcatheter mitral valve replacement, including patient selection, procedural techniques, and currently available outcomes.
287. Acute Lesion Visualization Following Interventional CMR Flutter Ablation Using PATRIOT CMR Imaging.
作者: Luuk H G A Hopman.;Nikki van Pouderoijen.;Michiel J B Kemme.;Raschel van Luijk.;Pranav Bhagirath.;Cornelis Allaart.;Marco J W Gotte.
来源: Circ Cardiovasc Imaging. 2025年e018540页 291. Letter by Ji and Zhang Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".292. Letter by He et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".294. Letter by Liu et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".295. Letter by Santini and Pola Regarding Article, "Rivaroxaban for 18 Months versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".297. Adipose Tissue in and Around the Heart: Structural and Functional Insights From Cardiac Magnetic Resonance.
作者: Andrea Barison.;Giovanni Donato Aquaro.;Santo Dellegrottaglie.;Stefania Rizzo.;Antonio De Luca.;Viviana Maestrini.;Alessandra Scatteia.;Andrea Baggiano.;Monica De Gaspari.;Pasquale Perrone Filardi.;Gianfranco Sinagra.;Massimo Imazio.;Cristina Basso.;Martina Perazzolo Marra.; .
来源: Circulation. 2025年152卷10期717-733页
Cardiac adipose tissue is normally present in the epicardium, but a variable amount can also be present in the myocardium, particularly in the subepicardial regions of the right ventricular anterolateral and apical regions. Pathological adipose tissue changes may occur in both ischemic (previous myocardial infarction) and nonischemic (previous myocarditis, arrhythmogenic cardiomyopathy, lipomatous hypertrophy of the interatrial septum, cardiac lipomas and liposarcomas) conditions, with or without extensive replacement-type myocardial fibrosis. Cardiac magnetic resonance is the gold standard imaging technique to characterize myocardial tissue changes and to distinguish between physiological and pathological cardiac fat deposits. In this review, we present the most common conditions presenting with myocardial fatty infiltration or with fatty replacement and the best magnetic resonance sequences to detect them, providing a comparison with histological findings and discussing their clinical significance.
298. Response by Yamashita et al to Letter Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".299. Patient and Physician Perspectives on Cardiovascular Risk: A Multicenter Survey of Communication Gaps Among Hospitalized Patients in Spain.
作者: Juan Górriz-Magaña.;Ramon Maruri-Sánchez.;Ane Elorriaga.;Nahikari Salterain-González.;Alicia Prieto-Lobato.;Raúl Gascueña Rubia.;Isabel Monedero Sánchez.;Ana Elvira-Laffond.;Miguel Lapena Reguero.;Amanda Leandro Barros.;Cristina Villabona Rivas.;Alejandro Gutiérrez-Fernández.;César Jiménez-Méndez.;Silvia Prieto-González.;María Melendo-Viu.;Blanca Alcón Durán.;Emilio Blanco López.;Clara Bonanad Lozano.;Alejandro Durante-López.;Anna Carrasquer.;Pedro Martínez-Losas.;Teresa Alvarado Casas.;Pedro Pájaro Merino.;Victor Juárez-Olmos.;Javier Lopez-Pais.;Michelle M Kittleson.;Pablo Díez-Villanueva.;Jordi Bañeras.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷10期e011837页
Effective risk communication is essential in managing cardiovascular disease, the leading cause of global mortality. Clear communication between patients and physicians supports informed decision-making, yet comprehension gaps persist. We aimed to assess the quality of risk communication during hospital admissions for cardiovascular events, from patient and physician perspectives, and identify discrepancies in risk perception and associated factors.
300. Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.
作者: Janelle M Wagnild.;Christopher Bayliss.;Rebecca H Maier.;Emmanuel Ogundimu.;Joseph Zacharias.;Enoch F Akowuah.
来源: Circulation. 2025年152卷17期1234-1245页
Wearable accelerometer devices measure free-living physical activity and sleep without relying on self-reports. Their utility to measure and compare recovery of physical function after cardiac surgery procedures has not been previously studied in the setting of a randomized controlled trial.
|